admin – Page 6080 – Get News Story

Cold Storage Market to Hit USD 12.22 Billion by 2029 – Market Size, Share, Trend Analysis & Forecasts – Exclusive Research Report by Arizton

“Cold Storage Market Research Report by Arizton”

The chilled storage segment, which typically refers to storage at temperatures between 0°C and 5°C, held the largest share of the global cold storage market in 2023.

According to the latest research report, the Cold Storage Market 2024-2029 by Arizton Advisory & Intelligence will grow at a CAGR of 7.70% during 2023-2029.

The global cold storage market plays a crucial role in maintaining the quality and safety of various products, including food and pharmaceuticals, by preserving them at specific temperatures. In addition, the cold storage market has been expanding steadily over the past few years and is expected to continue growing. Factors such as increasing demand for frozen and chilled food products, expanding pharmaceutical and healthcare industries, and the need for efficient supply chain management contribute to this growth.

Curious to Learn More,Click: https://www.arizton.com/market-reports/cold-storage-market

Report Summary

Market Size Revenue (2029): USD 12.22 Billion

Market Size Revenue (2023): USD 7.83 Billion

CAGR – Revenue (2023-2029): 7.70%

Market Size – Volume (2029): 1,064.52 million cubic meters

Historic Year: 2020-2022

Base Year: 2023

Forecast Year: 2024-2029

Market Segmentation: Warehouse Type, Facility Type, Temperature Type, Structure Type, Application, and Geography

Geographic Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa

Subscribe us for more updates: https://www.arizton.com/subscription

Refrigerated Warehouses Leading the Market

The global refrigerated warehouse market will reach $3.2 billion by 2029, growing at a CAGR of 6.94% during the forecast period.

Refrigerated warehouses maintain consistent temperature and humidity levels, preserving the quality, freshness, and nutritional value of perishable goods such as fruits, vegetables, meats, seafood, dairy products, and pharmaceuticals. By preventing spoilage, freezer burn, and microbial growth, these facilities extend the shelf life of products, reducing waste. Furthermore, in North America and Europe, the surge in e-commerce and online grocery shopping has led to greater demand for refrigerated warehouses capable of storing and distributing perishable goods for home delivery and click-and-collect services. As consumers embrace online grocery shopping, retailers and logistics providers invest in cold storage infrastructure to meet the demand for fresh and frozen products.

More than $4.8 Billion Growth Opportunities in the APAC Cold Storage Market

The cold storage market in APAC has been experiencing significant growth in recent years. According to GCCA, the region represents more than 300 cold chain suppliers and logistics providers in more than 15 countries. Hence, massive cold chain suppliers in the region significantly support the cold storage market.

China has released a National Logistics Hub Layout and Construction Plan to improve infrastructure and logistics capabilities, aiming to establish 150 advanced logistics hubs by 2025. In addition, during the 14th Five-Year Plan period (2021-2025), the country expects to set up 30 national and 70 regional cold-chain logistics bases for agricultural products. Similarly, the Indian government has also invested heavily in the industry and encouraged private participation through various subsidy schemes, such as the Pradhan Mantri Kisan Sampada Yojana and the Mission for Integrated Development of Horticulture scheme, both provide financial support in the form of grants-in-aid, such initiatives are positively impacting the cold storage market in the region.

To Know More, Click: https://www.arizton.com/market-reports/cold-storage-market

Key Company Profiles

Lineage Logistics Holding, LLC
Americold Logistics
United States Cold Storage, Inc
NewCold
Nichirei Corporation
Emergent Cold LatAM
The Tippmann Group
Constellation Cold Logistics
Superfrio Logistica Frigorificada
FreezPak Logistics
Conestoga Cold Storage
Congebec Logistics, Inc.
Metcold Holdings Limited
RLS Logistics
Friozem Armazens Frigorificos
Magnavale Ltd
Trenton Cold Storage
Nor-Am Cold Storage
Burris Logistics
Arihant Cold Storage
ColdStar Solutions Pvt Ltd
ColdStar Logistics
Coldman Logistics Pvt Ltd
Coldrush Logistics
Indicold Private Limited
Frialsa
Confederation Freezers (Premium Brands Holdings)
Vertical Cold Storage

Market Segmentation

Warehouse Type

Private
Public

Facility Type

Refrigerated Warehouse
Cold Rooms
Refrigerated Containers
Blast Freezers & Chillers
Other Facilities

Temperature Type

Chilled
Frozen
Deep Frozen

Structure Type

Civil Structure
Steel Structure
Hybrid Structure

Application

Dairy Products
Fish, Meat & Seafoods
Fruits & Vegetables
Bakery & Confectionery
Pharmaceuticals
Others

Geography

APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
North America
- The US
- Canada
Europe
- The UK
- Spain
- Germany
- France
- Italy
- Poland
Latin America
- Brazil
- Mexico
- Argentina
- Chile
Middle East & Africa
- South Africa
- Saudi Arabia
- The UAE
- Turkey

Check Out Some of the Latest Research Report that Can Boost your Business Decisions

Ice Storage Bins Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/ice-storage-bins-market

Vaccine Storage and Packaging Market – Global Outlook & Forecast 2021-2026

https://www.arizton.com/market-reports/vaccine-storage-and-packaging-market

Why Arizton?                        

100% Customer Satisfaction                        

24×7 availability – we are always there when you need us                        

200+ Fortune 500 Companies trust Arizton’s report                        

80% of our reports are exclusive and first in the industry                        

100% more data and analysis                        

1500+ reports published till date                         

About Us:                                                             

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                           

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                            

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.            

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040
Country: United States
Website: https://www.arizton.com/market-reports/cold-storage-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cold Storage Market to Hit USD 12.22 Billion by 2029 – Market Size, Share, Trend Analysis & Forecasts – Exclusive Research Report by Arizton

Soft Tissue Sarcoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2024” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Soft Tissue Sarcoma Research. Learn more about our innovative pipeline today! @ Soft Tissue Sarcoma Pipeline Outlook

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report

July 2024:- Epizyme Inc.- A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma. The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
July 2024:- Nationwide Children’s Hospital- This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas.
DelveInsight’s Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
The leading Soft Tissue Sarcoma Companies such as Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Promising Soft Tissue Sarcoma Therapies such as Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.

Stay informed about the cutting-edge advancements in Soft Tissue Sarcoma Treatments. Download for updates and be a part of the revolution in oncology care @ Soft Tissue Sarcoma Clinical Trials Assessment

Soft Tissue Sarcoma Emerging Drugs Profile

AL3818: Advenchen Laboratories

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells. More specifically, the mechanism involves the inhibition of the downstream ERK signaling pathway. Anlotinib has stronger anti-angiogenesis activity than that do other antiangiogenic agents (sunitinib and sorafenib). Currently, it is in Phase III stage of clinical trial evaluation to treat Soft Tissue Sarcoma.

L19 TNF: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has previously been studied in clinical trials as monotherapy for systemic administration in patients with solid tumors and in melanoma patients using the Isolated Limb-Perfusion procedure. In preclinical models of sarcoma, Fibromun has, when combined with doxorubicin or dacarbazine (which are standard therapies for first line and third line sarcoma, respectively), cured all treated animals . Based on the encouraging results observed in the phase Ib study conducted in patients with metastatic Soft Tissue Sarcoma, three clinical trials with registration potential have started in Europe and in the United States. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Soft tissue sarcoma.

Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types. The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase IIα isoform achieves the anticancer effect, while inhibiting the topoisomerase IIβ isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase IIα isoform over the topoisomerase IIβ isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.

Learn more about Soft Tissue Sarcoma Drugs opportunities in our groundbreaking Soft Tissue Sarcoma Research and development projects @ Soft Tissue Sarcoma Unmet Needs

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Soft Tissue Sarcoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspectives

Scope of the Soft Tissue Sarcoma Pipeline Report

Coverage- Global
Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Soft Tissue Sarcoma Therapies- Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.
Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Soft Tissue Sarcoma Pipeline on our website @ Soft Tissue Sarcoma Drugs and Companies

Table of Content

Introduction
Executive Summary
Soft Tissue Sarcoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Anlotinib: Advenchen Laboratories, LLC
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Camsirubicin: Monopar Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
FHD-609: Foghorn Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Soft Tissue Sarcoma Key Companies
Soft Tissue Sarcoma Key Products
Soft Tissue Sarcoma- Unmet Needs
Soft Tissue Sarcoma- Market Drivers and Barriers
Soft Tissue Sarcoma- Future Perspectives and Conclusion
Soft Tissue Sarcoma Analyst Views
Soft Tissue Sarcoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Idiopathic Pulmonary Fibrosis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Idiopathic Pulmonary Fibrosis Research. Learn more about our innovative pipeline today! @ Idiopathic Pulmonary Fibrosis Pipeline Outlook

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

June 2024:- Tvardi Therapeutics, Incorporated- REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis. The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
June 2024:- Pliant Therapeutics, Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF). The study will consist of an up to 35-day Screening Period, a 52-week Treatment Period, and a 14 day Safety Follow-up Period. Of note, participants who are not taking background therapy at study entry will be allowed to initiate it at any time during the study.
June 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
DelveInsight’s Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
Promising Idiopathic Pulmonary Fibrosis Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, and others.

Stay informed about the cutting-edge advancements in Idiopathic Pulmonary Fibrosis Treatments. Download for updates and be a part of the revolution in respiratory disease care @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

Idiopathic Pulmonary Fibrosis Emerging Drugs

Pamrevlumab: FibroGen

Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

Tipelukast: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. The US Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Currently, the drug is in the Phase II stage of its development for the treatment of IPF.

PLN-74809: Pliant Therapeutics

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) in IPF and Orphan Drug Designation from the European Medicines Agency (EMA) in IPF. The company has completed enrollment in the Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) and announced positive data from the trial.

HZN-825: Horizon Pharmaceuticals

HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

Brilaroxazine: Reviva Pharmaceuticals

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF). Serotonin (5-HT) signaling plays a key role, via 5-HT2A/2B/7 receptors, in the vasoactive effect on pulmonary arteries and lung myofibroblast actions. Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter. Brilaroxazine’s effects on vascular fibrosis (5-HT2B receptor), proliferation (5-H2A/2B receptor), relaxation (5-HT2A receptor), inflammation (5-HT7 receptor), and pro-inflammatory cytokines have created interest in the potential to treat IPF. Brilaroxazine was evaluated in a bleomycin (BLM)-induced rat model of IPF receiving either brilaroxazine 15 mg twice daily for 21 days starting at day 1 (BT) or at day 10 (BI) and demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF. Currently, the drug is in the Phase I stage of its development for the treatment of IPF.

Learn more about Idiopathic Pulmonary Fibrosis Drugs opportunities in our groundbreaking Idiopathic Pulmonary Fibrosis Research and development projects @ Idiopathic Pulmonary Fibrosis Unmet Needs

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
Intravitreal
Subretinal
Topical

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Idiopathic Pulmonary Fibrosis Treatment by visiting our website. Stay informed about how we’re transforming the future of respiratory disease @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

Coverage- Global
Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
Idiopathic Pulmonary Fibrosis Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, and others.
Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Idiopathic Pulmonary Fibrosis Pipeline on our website @ Idiopathic Pulmonary Fibrosis Drugs and Companies

Table of Content

Introduction
Executive Summary
Idiopathic Pulmonary Fibrosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Pamrevlumab: FibroGen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tipelukast: MediciNova
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Brilaroxazine: Reviva Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Idiopathic Pulmonary Fibrosis Key Companies
Idiopathic Pulmonary Fibrosis Key Products
Idiopathic Pulmonary Fibrosis- Unmet Needs
Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
Idiopathic Pulmonary Fibrosis Analyst Views
Idiopathic Pulmonary Fibrosis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

WSIMLogiX Elevates Online Success for Businesses with Expert SEO Services

Discover how WSIMLogiX boosts business success with expert SEO services, driving growth and ROI in the competitive digital landscape.

Danville, California – July 2, 2024 – WSIMLogiX, the leading digital marketing and advertising agency offers advanced, customizable digital marketing solutions designed to help businesses unlock their full revenue potential. Specializing in SEO services, WSIMLogiX is the best Bay Area SEO company, offering unparalleled expertise to drive online growth and customer retention for businesses of all sizes.

Over the years, their top-tier SEO services companies not only reach their business goals but also maintain a competitive edge in the digital marketplace. Leveraging their team of seasoned Bay Area SEO experts, WSIMLogiX crafts strategic campaigns tailored to meet the unique needs of each client, facilitating quick, sustainable growth and impressive returns on investment (ROIs).

“Our team is unrivaled in its ability to create an outstanding online presence for any company, whether it’s a start-up or a well-established business,” says a spokesperson for the company. “We understand that every business is different, and that’s why we offer customizable solutions to ensure our clients stand out online and make a lasting impression on their customers.”

As one of the certified SEO services Bay Area, WSIMLogiX combines advanced strategies with industry-leading experience to elevate the customer journey from start to finish. They offer an array of services including SEO, Google Ads, web development, social media marketing, email marketing, and more.

The agency’s commitment to fast-paced results means clients can expect to see remarkable growth earlier than expected. By investing in WSIMLogiX’s services on SEO Bay Area, businesses can watch their revenue soar and realize impressive ROIs, positioning themselves for long-term success in the ever-evolving digital landscape.

“The market segments that we currently serve include Quick service restaurant chains, health care, and medical insurance, finance service, industrial automation, and more. Our focus is to get the right customers to the right businesses all the time that significantly increases brand awareness and profitable revenue,” said the spokesperson.

To know more about their marketing services or to schedule a consultation, visit the company’s website.

About Company:

WSIMLogiX is one of the recognized companies offering tailored digital marketing strategies that help businesses grow. To know more, visit https://wsimlogix.com/

Media Contact
Company Name: WSIMlogiX
Contact Person: Niveditha Jain
Email: Send Email
Phone: +1 (408) 341-5845
Address:3005 Drysdale St
City: Danville
State: California
Country: United States
Website: https://wsimlogix.com/

ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “ANCA Vasculitis Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in ANCA Vasculitis Research. Learn more about our innovative pipeline today! @ ANCA Vasculitis Pipeline Outlook

Key Takeaways from the ANCA Vasculitis Pipeline Report

June 2024:- Amgen- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
June 2024:- Alpine Immune Sciences Inc.- An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3). The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases.
DelveInsight’s ANCA Vasculitis pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
Promising ANCA Vasculitis Therapies such as BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.

Stay informed about the cutting-edge advancements in ANCA Vasculitis Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases care @ ANCA Vasculitis Clinical Trials Assessment

ANCA Vasculitis Emerging Drugs Profile

Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

Learn more about ANCA Vasculitis Drugs opportunities in our groundbreaking ANCA Vasculitis Research and development projects @ ANCA Vasculitis Unmet Needs

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in ANCA Vasculitis Treatment by visiting our website. Stay informed about how we’re transforming the future of cardiovascular disease @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives

Scope of the ANCA Vasculitis Pipeline Report

Coverage- Global
ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
ANCA Vasculitis Therapies- BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.
ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of ANCA Vasculitis Pipeline on our website @ ANCA Vasculitis Drugs and Companies

Table of Content

Introduction
Executive Summary
ANCA Vasculitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
ANCA Vasculitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Abatacept: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Sparsentan: Travere Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
ANCA Vasculitis Key Companies
ANCA Vasculitis Key Products
ANCA Vasculitis- Unmet Needs
ANCA Vasculitis- Market Drivers and Barriers
ANCA Vasculitis- Future Perspectives and Conclusion
ANCA Vasculitis Analyst Views
ANCA Vasculitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Electroceuticals/Bioelectric Medicine Market worth $33.6 billion by 2029 | MarketsandMarkets™

“The major players in this market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China)”

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall electroceuticals market and its subsegments.

Electroceuticals Market / Bioelectric Medicine Market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets™. The increasing elderly population and rising incidences of cardiovascular and neurological disorders worldwide are driving the market’s growth. Bioelectric medicine employs deep brain, vagus sacral, and transcutaneous electric nerve stimulators to treat these conditions. Additionally, the growing prevalence of arrhythmia, which requires the use of implantable cardioverter-defibrillators and cardiac pacemakers, is another growth driver. The market is also benefiting from the growing demand for non-invasive medical treatments, technological advancements, and a growing body of research demonstrating the efficacy of this technology. The development of new, more advanced electroceutical devices and therapies, such as implantable neurostimulators and transcutaneous electrical nerve stimulation (TENS) devices, is further propelling market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222053956

The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market, by product segment, in 2022

Based on product, the electroceuticals market is segmented into cardiac pacemakers & implantable cardioverter defibrillators, neuromodulators, cochlear implants, and retinal implants. The cardiac pacemakers & implantable cardioverter defibrillators segment accounted for the largest share of the electroceuticals market in 2022, primarily due to the increasing prevalence of cardiovascular disorders worldwide. Additionally, the rising incidence of sudden cardiac arrests, a growing elderly population, and advancements in product development are anticipated to drive market growth.

Non-invasive electroceutical devices segment to register the highest growth rate during the forecast period

The electroceuticals market is divided into two segments: implantable electroceutical devices and non-invasive electroceutical devices. In 2022, the noninvasive electroceutical devices segment experienced the highest growth rate. This growth is attributed to factors such as increased R&D investments by companies for novel product development and technological advancements in this segment.

Arrhythmia segment accounted for the largest share of the electroceuticals market, by product segment, in 2022

Based on application, the electroceuticals market is segmented into arrhythmia, chronic pain management, Parkinson’s disease, urine incontinence, depression, epilepsy, and others. In 2022, the arrhythmia segment emerged as the dominant force in the overall market. This dominance is fueled by the rising prevalence of arrhythmia, a condition often managed with implantable cardioverter-defibrillators and cardiac pacemakers.

North America is the largest regional market for electroceuticals market

The global electroceuticals market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, North America held the largest market share in the electroceuticals market in 2022. A significant share in North America can be attributed to the presence of major medical device manufacturers like Abbott and Boston Scientific Corporation. The region’s well-established healthcare system and access to advanced products have further propelled market growth. Following North America, Europe secured the second position, fueled by the increasing demand for innovative medical devices for treatment. The region’s robust healthcare infrastructure and the presence of major bioelectric medicine manufacturers are expected to continue driving market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222053956

Electroceuticals Market / Bioelectric Medicine Market Dynamics:

Drivers:

The increasing elderly population and subsequent rise in the prevalence of neurological and cardiovascular disorder

Restraints:

The high cost associated with electroceutical devices

Opportunities:

Emerging markets present attractive opportunities

Challenge:

The shortage of skilled professionals

Key Market Players of Electroceuticals Market / Bioelectric Medicine Industry:

The major players in this market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China), Sonova Group (Switzerland), Nevro Corp. (US), Axonics Modulation Technologies, Inc. (US), Neuronetics, Inc. (US), ElectroCore, Inc. (US), NeuroPace, Inc. (US), BIOTRONIK (Germany), Medico S.p.A. (Italy), Nurotron Biotechnology Co. Ltd. (US), MED-EL (Austria), Aleva Neurotherapeutics SA (Switzerland), NeuroSigma, Inc. (US), BioWave Corporation (US), Soterix Medical Inc. (US), Bioinduction (Amber Therapeutics) (UK), GiMer Medical (Taiwan), Cefaly (Belgium), BioControl Medical (Israel), and tVNS Technologies GmbH (Germany).

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 – 28%, Tier 2 – 42%, and Tier 3 -30%
By Designation: C-level – 30%, D-level – 34%, and Others – 36%
By Region: North America – 46%, Europe – 25%, Asia Pacific – 18%, and Rest of the World -11%

Recent Developments of Electroceuticals Market / Bioelectric Medicine Industry:

In January 2024, Medtronic plc (Ireland) received FDA approval of its Percept RC Deep Brain Stimulation (DBS) system.
In July 2023, Boston Scientific Corporation (US) received the US FDA approval for the vercise neural navigator 5 software, which when used as part of the vercise genus deep brain stimulation (dbs) systems.
In May 2023, Abbott (US) received US FDA approval for its spinal cord stimulation (SCS) devices for the treatment of chronic back pain.
In Dec 2022, ElectroCore (US) launched a new wellness product offering called Truvaga for customers residing in the US. Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to activate the vagus nerve quickly and gently.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=222053956

Electroceuticals Market / Bioelectric Medicine Market – Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall electroceuticals market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/electroceutical-market-222053956.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electroceuticals/Bioelectric Medicine Market worth $33.6 billion by 2029 | MarketsandMarkets™

GROKR Exchange: Leading the New Era of Digital Currency Trading

In today’s rapidly growing global digital currency market, GROKR Exchange has quickly emerged as a formidable force in the cryptocurrency trading sector, thanks to its innovative technology platform and comprehensive services. As a compliant platform regulated by the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN), GROKR Exchange has been committed to providing users with a secure, transparent, and efficient trading environment since its inception.

One of GROKR Exchange’s key advantages is the variety and number of trading pairs it supports. Currently, the platform supports over 253 cryptocurrencies, offering 512 trading pairs, covering nearly all mainstream and emerging digital assets in the market. This not only provides users with a wide range of investment options but also caters to investors with different risk preferences by offering personalized trading strategies. Whether one is a long-term investor seeking stability or an active trader favoring short-term transactions, GROKR Exchange has suitable trading opportunities.

Technology is another cornerstone of GROKR Exchange. The platform utilizes an advanced matching engine to ensure fast execution of trades and system stability. Additionally, GROKR Exchange has implemented multiple layers of security measures, including cold storage, multi-signature technology, and real-time monitoring systems, to safeguard users’ assets. These measures significantly reduce security risks during the trading process, providing robust protection for users’ funds.

Enhancing user experience is a continual goal for GROKR Exchange. The platform offers a user-friendly interface and intuitive operational processes, ensuring that both newcomers to cryptocurrency trading and seasoned traders can enjoy a seamless trading experience. Moreover, GROKR Exchange provides a wealth of educational resources and market analysis tools to help users better understand market dynamics and improve their analytical and decision-making abilities.

On February 18, 2022, GROKR Exchange achieved a remarkable milestone by reaching a trading volume of $117 million within 24 hours. This achievement not only demonstrates the platform’s strong liquidity and activity but also reflects its significant position in the global cryptocurrency market. This success is attributed to GROKR Exchange’s continuous investment in technology, user experience, and market expansion.

Looking ahead, GROKR Exchange plans to continue expanding its service range by adding more trading pairs and financial products to meet the growing market demand. The vision of GROKR Exchange is to build a global digital asset trading ecosystem that provides secure, reliable, and user-friendly services, enabling more people to participate in digital currency trading and share in the prosperity of the digital economy. With ongoing technological advancements and market growth, GROKR Exchange is steadily progressing towards this ambitious goal.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: GROKR Exchange Ltd.
Contact Person: ERNEST DEWEY MAY JR
Email: Send Email
Country: United States
Website: https://grokrlssc.com/

Mastering GST Billing: A Comprehensive Guide to Compliance and Efficiency

When it comes to managing your business, efficiency and compliance are paramount. One area where this is particularly crucial is GST billing. With the right approach and tools, you can streamline your processes, ensure compliance, and make your business operations smoother. Here are the essentials of GST billing and how you can master it with the help of GST billing software.

Why GST Billing Matters?

First, let’s understand why GST billing is so important. The Goods and Services Tax (GST) is a comprehensive, multi-stage, destination-based tax levied on every value addition. Businesses must comply with GST regulations to avoid penalties and ensure smooth operations. Proper GST billing not only ensures compliance but also improves transparency and accuracy in your financial transactions.

The Essentials of GST Billing

What is GST Billing?

GST billing involves generating invoices that comply with GST regulations. These invoices must contain specific details such as the supplier’s and recipient’s GSTIN, invoice number, date, taxable value, tax rate, and the amount of tax charged. Omitting any of these details can result in non-compliance issues.

Key Components of a GST Invoice

A proper GST invoice should include the following:

– Supplier’s Details:

Name, address, and GSTIN.

– Recipient’s Details:

Name, address, and GSTIN (if registered).

– Invoice Number:

A unique sequential number.

– Date:

The date of issue.

– Description of Goods/Services:

Provide a clear description with HSN/SAC codes.

– Taxable Value:

The value before tax.

– GST Rates:

Applicable CGST, SGST, and IGST rates.

– Total Amount:

This includes tax and any additional charges.

Importance of Accuracy

Accuracy in GST billing is non-negotiable. Errors can lead to penalties and complicate your tax filings. This is where the efficiency of GST billing software becomes evident. Such software ensures that all necessary details are captured and compliant with GST norms.

How GST Billing Software Enhances Efficiency

Automating the Process

One of the biggest advantages of using GST billing software is automation. It significantly reduces the time and effort required to generate invoices. This automation helps minimize human errors and ensures that your invoices are always correct.

Real-Time Updates

GST laws and rates can change. GST billing software usually comes with real-time updates, ensuring that your billing practices are always in line with the latest regulations. This feature saves you from the hassle of manually updating your billing system and reduces the risk of non-compliance.

Comprehensive Record-Keeping

Maintaining records is crucial for GST compliance. GST billing software helps you keep comprehensive records of all your transactions. These records are essential during audits and for filing returns. With all your invoices stored digitally, retrieving any information becomes a matter of seconds.

Choosing the Right GST Billing Software

Features to Look For

When choosing GST billing software, look for the following features:

– User-Friendly Interface:

Easy to navigate and use.

– Compliance Assurance:

Regular updates to stay compliant with GST laws.

– Customization:

Ability to customize invoices as per your business needs.

– Integration:

Seamless integration with your accounting software.

Conclusion

Mastering GST billing is essential for the smooth operation of your business. By understanding the key components of GST billing and leveraging GST billing software, you can ensure compliance, improve efficiency, and focus on what you do best – running your business. So, take the time to explore your options and choose the right GST billing software that fits your needs.

Media Contact
Company Name: CaptainBiz
Contact Person: Chetan Morajkar
Email: Send Email
Phone: 9833276867
Country: India
Website: https://www.captainbiz.com/

Quantmove Smart Markets releases a new data security protocol, significantly meeting the security needs of global users.

On July 1, Quantmove Smart Markets Limited (QSM) announced the release of its latest data security protocol, addressing the increasing demands of the digital age and significantly enhancing data security for its global users. This new protocol marks a substantial advancement in QSM’s commitment to data protection, aiming to provide users with state-of-the-art security assurance.

In today’s rapidly evolving digital economy and fintech landscape, data security is a critical concern for both users and businesses. QSM focuses on maximizing asset value for its clients through proprietary quantitative trading algorithms and an intelligent investment platform. With a growing user base and expanding transaction volumes, the importance of data security has never been more pronounced. Chris Weston, QSM’s external affairs representative, stated, “We understand the critical importance of data security to our users, and we are continually enhancing our security measures to ensure the highest level of protection for user transactions and data.”

The newly released data security protocol incorporates several innovative measures designed to significantly enhance the platform’s security performance. First, QSM has integrated advanced encryption technology to ensure that user data remains highly encrypted during both transmission and storage. Additionally, QSM has implemented multi-layer authentication mechanisms, including biometric verification and two-factor authentication, greatly enhancing account security. The company has also established real-time monitoring and alert systems to quickly detect and respond to any potential security threats, ensuring the platform’s stability and security.

To ensure the smooth implementation and promotion of the new protocol, QSM has launched a series of user education and training initiatives. The company uses online webinars, technical lectures, and platform announcements to help users understand and adopt the new security measures and operational guidelines. Additionally, QSM provides 24/7 customer support to promptly address any issues users may encounter during use.

The release of this data security protocol is a significant initiative in QSM’s technological innovation and user service strategy, underscoring the company’s strong commitment to user security and interests. Moving forward, QSM plans to continue investing heavily in security technology to maintain its technological edge, continuously enhancing the platform’s security and stability. Through ongoing technological innovation and service optimization, QSM is dedicated to providing the highest quality financial trading experience for users worldwide, helping them preserve and grow their assets.

In summary, QSM’s latest upgrade not only boosts platform security but also strengthens user trust and reliance. Financial analysts widely view QSM’s investment in data security favorably, believing it will increase the company’s competitiveness and user loyalty in the global market. If QSM continues to innovate technologically and improve user services, it could become a secure, stable, and leading international platform.

Media Contact
Company Name: Quantmove Smart Markets Limited
Contact Person: Lion
Email: Send Email
Country: United States
Website: https://www.qmovsi.com/

Minimally Invasive Surgery Market worth $173.9 billion by 2029

“North America is propelled by factors such as a growing aging population, a high incidence of chronic disorder, a rise in demand for minimally invasive surgical procedures, and the presence of strong players with robust minimally invasive surgery portfolios.”

Browse 310 market data Tables and 67 Figures spread through 359 Pages and in-depth TOC on “Minimally Invasive Surgery Market by Product (Robotics, Imaging, Instrument (Handheld, inflation, Guiding, electrosurgery, endoscopy)), Application (CVD, thoracic, neuro, ENT, OB/GYN, orthopedic), End-user, and Surgery volume – Global Forecast to 2029

The report “Minimally Invasive Surgery Market by Product (Robotics, Imaging, Instrument (Handheld, inflation, Guiding, electrosurgery, endoscopy)), Application (CVD, thoracic, neuro, ENT, OB/GYN, orthopedic), End-user, and Surgery volume – Global Forecast to 2029”, is projected to reach USD 173.9 billion by 2029 from USD 79.3 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The expansion of the minimally invasive surgery market is propelled by several synergistic factors, including increasing demand for MIS procedures, escalating chronic disorder prevalence, increasing geriatric patient population, rising public-private investments to support for the clinical research and the presence of key market players in developing regions.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=787

Imaging & Visualization systems segment to register a significant growth rate over the forecast period of 2023-2029.

Based on the product, the minimally invasive surgery market is segmented into Surgical Devices, Imaging & Visualization Systems, Endoscopy Devices, Electrosurgical Devices, and Medical Robotics. The surge in chronic disorder and less invasive surgical procedures often involve imaging systems to visualize the affected area. Furthermore, these innovations provide surgeons with enhanced clarity and precision in observing the surgical site, resulting in reduced tissue trauma, shorter operative durations, expedited patient recovery, and improved overall outcomes.

Cardio-thoracic surgery segment accounted for the significant share of the minimally invasive surgery market in 2023-2029.

Based on the application, cardio-thoracic segment accounts largest market share in minimally invasive surgery market. Key drivers propelling the adoption of minimally invasive surgery (MIS) in cardio-thoracic procedures encompass technological advancements, particularly in precision surgical tools and imaging modalities. As clinicians accrue expertise in MIS methodologies, they exhibit greater confidence in applying these techniques to intricate cardio-thoracic interventions. Additionally, evolving healthcare policies and reimbursement frameworks incentivizing cost-effective and streamlined treatment pathways further bolster the uptake of MIS in cardio-thoracic surgery

North America to account for a significant market share in the minimally invasive surgery market in 2023.

Based on region, The minimally invasive surgery market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with North America dominating the market share in 2023. This dominance in North America is propelled by factors such as a growing aging population, a high incidence of chronic disorder, a rise in demand for minimally invasive surgical procedures, and the presence of strong players with robust minimally invasive surgery portfolios. Furthermore, growing research and funding initiatives from public and private organizations are expected to further boost the minimally invasive surgery market in North America.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=787

Minimally Invasive Surgery Market Dynamics:

Drivers:

1. Increase adoption of MIS over open surgeries

Restraints:

1. High cost of Robotic systems

Opportunities:

1. Emerging markets- growth opportunities

Challenge:

1. High degree of market consolidaton

Key Market Players of Minimally Invasive Surgery Industry:

As of 2023, prominent players in the minimally invasive surgery market are Medtronic (Ireland), Johnson & Johnson (US), NuVasive (US), Becton, Dickinson & Co. (US), Stryker Corporation (US), Zimmer Biomet Holdings (US), Abbott Laboratories (US) and Boston Scientific Corporation (US), GE healthcare (US), among others.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
By Designation: C-level– 27%, Director-level–18%, and Others–55%
By Region: North America–50%, Europe-20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Recent Developments of Minimally Invasive Surgery Industry:

In 2023, Medtronic receives CE Mark approval for Affera Mapping and Ablation System to treat atrial arrhythmias.
In 2023, J&J MONARCH Platform is the first minimally invasive, robotic-assisted technology approved for bronchoscopy in China with significant burden of lung cancer.
In 2023, Stryker’s Q Guidance System for cranial applications received US FDA clearance to support cranial surgeries.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=787

Minimally Invasive Surgery Market – Key Benefits of Buying the Report:

The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the minimally invasive surgery market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Minimally Invasive Surgery Market worth $173.9 billion by 2029